丁酸内酯I T25192

Product Introduction
Bioactivity


英文名: Butyrolactone I

描述: Butyrolactone I (Olomoucin) 是 CDK 和 cdc2 激酶家族的 ATP 竞争性抑制剂。 Butyrolactone I 在非小细胞肺、小细胞肺和前列腺癌细胞系中显示出抗肿瘤作用。

体外活性: Butyrolactone I (70 and 100 μM) increases the percentage of DU145 cells in the 4C phase of the cell cycle. Butyrolactone I increases the amount of cyclin B1 positive cells in the 4C phase on day 1 and returns to normal by day 3. Butyrolactone I inhibits Cdc2 of unsynchronized cultured prostate cancer cells and interrupts the cell cycle progression toward cell division. The Butyrolactone I inhibition of Cdc2 led to the accumulation of cells in the 4C phase without mitosis resulting in an accumulation of cyclin B1[3].

存储条件: store at low temperaturePowder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Butyrolactone I

相关产品: Tacaciclib | Rigosertib | LY3177833 | CLK1-IN-3 | Olomoucine | AM5992 | Ribociclib succinate hydrate | THZ1-R | Indoramin D5 | AT7519

相关库: Rare Natural Product Library

丁酸内酯I T25192信息由TargetMol中国为您提供，如您想了解更多关于丁酸内酯I T25192报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途